Cannabidiol (CBD) has demonstrated therapeutic potential across multiple indications, including epilepsy, anxiety, pain, and inflammatory disorders.
Conventional CBD is water insoluble, and thus presents pharmacokinetic limitations, mainly low and variable systemic exposure. Oral CBD exhibits low and inconsistent absorption, significant interpatient variability, and dose inefficiency, often requiring high doses to achieve therapeutic concentrations.
To address these fundamental limitations, Trait Biosciences developed Trait VitaComplex— the company’s proprietary line of structurally modified, water-soluble cannabinoid active pharmaceutical ingredients (APIs). Trait VitaComplex is innovated to overcome the aqueous incompatibility of conventional CBD at the molecular level, thereby enabling improved pharmacokinetic performance.
Trait Biosciences’s VitaComplex technology involves proprietary enzymatic and chemical processes that convert conventional water-insoluble CBD into water-soluble active pharmaceutical ingredients. The improved hydrophilic character of Trait VitaComplex enhances interaction with physiological fluids and improves membrane permeability.
In ex vivo testing, Trait VitaComplex achieved approximately 300× higher intestinal permeation compared to conventional CBD, thereby enabling significantly more compound to cross the intestinal barrier and enter systemic circulation.
When applied to epithelial tissue ex vivo, Trait VitaComplex demonstrated approximately 10× higher epithelial transport, indicating accelerated trans-epithelial movement and faster absorption kinetics.
Together, these findings support both increased bioavailability and a faster onset of action — critical priorities in oral therapeutic function.
By improving aqueous compatibility at the molecular level, Trait VitaComplex:
- Increases systemic exposure
• Reduces variability across patients
• Improves dose efficiency
• Supports more predictable plasma concentration profiles
• Enhances transport within systemic circulation and therefore distribution to target tissues
These advantages are relevant across different routes of administration — oral, inhalation, injectable, and topical — where efficient systemic uptake determines therapeutic performance.
Patented technology, and produced at scale, Trait VitaComplex is positioned to support both OTC and prescription development pathways.
